BACKGROUND: Apolipoprotein E varepsilon4 (APOE varepsilon4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE varepsilon4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). METHODS: A total of 516 aMCI participants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE varepsilon4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. RESULTS: APOE varepsilon4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE varepsilon4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. CONCLUSIONS: These findings demonstrate that APOE varepsilon4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE varepsilon4 status needs to be accounted for in treatment trials of MCI. Copyright 2010 The Alzheimer
BACKGROUND:Apolipoprotein E varepsilon4 (APOE varepsilon4) allele carrier status has been well established as a risk factor for developing Alzheimer's disease. However, the specific influence of APOE varepsilon4 allele status on cognitive and functional rates of decline in mild cognitive impairment (MCI) is poorly understood. We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI). METHODS: A total of 516 aMCIparticipants aged 55-90 years who received placebo or vitamin E from the Alzheimer's Disease Cooperative Study's MCI treatment trial were evaluated. During the 36-month study period, neurocognitive and functional measures were collected. These measures were assessed over time for change and association with APOE varepsilon4 status. Generalized Estimating Equations were performed to model each outcome measure over the study period. RESULTS:APOE varepsilon4 status had a significant impact on cognitive and functional decline on multiple measures; those who were APOE varepsilon4 positive had significantly more rapid decline in performance on all cognitive and functional measures except Number Cancellation and Maze tracing (P < .05). The greatest decline was seen in global measures of cognition and function including the Clinical Diagnostic Rating scale, followed by the Mini-Mental State Examination, Global Deterioration scale, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale. CONCLUSIONS: These findings demonstrate that APOE varepsilon4 genotype is predictive of increased general rates of decline with global measures of cognition and function most affected. With accelerated declines in common clinical trial primary efficacy measures, APOE varepsilon4 status needs to be accounted for in treatment trials of MCI. Copyright 2010 The Alzheimer
Authors: R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal Journal: Alzheimer Dis Assoc Disord Date: 1997 Impact factor: 2.703
Authors: R J Caselli; N R Graff-Radford; E M Reiman; A Weaver; D Osborne; J Lucas; A Uecker; S N Thibodeau Journal: Neurology Date: 1999-07-13 Impact factor: 9.910
Authors: Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal Journal: N Engl J Med Date: 2005-04-13 Impact factor: 91.245
Authors: Eric M Reiman; Kewei Chen; Xiaofen Liu; Daniel Bandy; Meixiang Yu; Wendy Lee; Napatkamon Ayutyanont; Jennifer Keppler; Stephanie A Reeder; Jessica B S Langbaum; Gene E Alexander; William E Klunk; Chester A Mathis; Julie C Price; Howard J Aizenstein; Steven T DeKosky; Richard J Caselli Journal: Proc Natl Acad Sci U S A Date: 2009-04-03 Impact factor: 11.205
Authors: M C Tierney; J P Szalai; W G Snow; R H Fisher; T Tsuda; H Chi; D R McLachlan; P H St George-Hyslop Journal: Neurology Date: 1996-01 Impact factor: 9.910
Authors: Arvind Nishtala; Sarah R Preis; Alexa Beiser; Sherral Devine; Lisa Hankee; Sudha Seshadri; Philip A Wolf; Rhoda Au Journal: Alzheimer Dis Assoc Disord Date: 2014 Jan-Mar Impact factor: 2.703
Authors: Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian Journal: Brain Date: 2018-07-01 Impact factor: 13.501
Authors: Nicolas Farina; Mokhtar Gad El Kareem Nasr Isaac; Annalie R Clark; Jennifer Rusted; Naji Tabet Journal: Cochrane Database Syst Rev Date: 2012-11-14
Authors: Chelsea C Hays; Zvinka Z Zlatar; M J Meloy; Mark W Bondi; Paul E Gilbert; Thomas T Liu; Jonathan L Helm; Christina E Wierenga Journal: Neuroimage Date: 2019-09-04 Impact factor: 6.556
Authors: Chelsea C Hays; Zvinka Z Zlatar; M J Meloy; Mark W Bondi; Paul E Gilbert; Thomas Liu; Jonathan L Helm; Christina E Wierenga Journal: Brain Imaging Behav Date: 2020-04 Impact factor: 3.978